Last edition
News about "Ispen, Exicure ink collaboration to research, deve"
Ipsen and Exicure have signed an exclusive collaboration agreement to research, develop, and commercialize novel spherical nucleic acids (SNAs) as potential investigational treatments for Huntington's disease and Angelman syndrome
Ispen, Exicure Ink Collaboration To Research, Deve | 03/08/2021 | By Darshana | 177
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members